epigallocatechin gallate has been researched along with alloxan in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdeen, S; Chapman, E; Chitre, S; Hoang, QQ; Johnson, SM; Park, Y; Ray, AM; Salim, N; Sivinski, J; Stevens, M; Washburn, A | 1 |
| Adnan, M; Badraoui, R; Ben-Nasr, H; Chappard, D; El-Feki, A; Gargouri, M; Kausar, MA; Magné, C; Saeed, M; Siddiqui, AJ; Snoussi, M; Soussi, A | 1 |
2 other study(ies) available for epigallocatechin gallate and alloxan
| Article | Year |
|---|---|
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Topics: Biological Products; Chaperonin 10; Chaperonin 60; Escherichia coli; Humans; Inhibitory Concentration 50; Protein Folding; Rafoxanide; Salicylanilides; Suramin | 2019 |
(-)-Epigallocatechin gallate (EGCG) pharmacokinetics and molecular interactions towards amelioration of hyperglycemia, hyperlipidemia associated hepatorenal oxidative injury in alloxan induced diabetic mice.
Topics: Alloxan; Animals; Antioxidants; Blood Glucose; Catechin; Diabetes Mellitus, Experimental; Hyperglycemia; Hyperlipidemias; Liver; Mice; Oxidative Stress | 2022 |